CTSO vs. NPCE, DCTH, PROF, DRTS, ARAY, CLPT, HSAQ, CVRX, QIPT, and TELA
Should you be buying Cytosorbents stock or one of its competitors? The main competitors of Cytosorbents include NeuroPace (NPCE), Delcath Systems (DCTH), Profound Medical (PROF), Alpha Tau Medical (DRTS), Accuray (ARAY), ClearPoint Neuro (CLPT), Health Sciences Acquisitions Co. 2 (HSAQ), CVRx (CVRX), Quipt Home Medical (QIPT), and TELA Bio (TELA). These companies are all part of the "surgical & medical instruments" industry.
Cytosorbents (NASDAQ:CTSO) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends, community ranking and analyst recommendations.
NeuroPace has a net margin of -45.61% compared to Cytosorbents' net margin of -75.07%. Cytosorbents' return on equity of -129.89% beat NeuroPace's return on equity.
In the previous week, NeuroPace had 1 more articles in the media than Cytosorbents. MarketBeat recorded 5 mentions for NeuroPace and 4 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 1.19 beat NeuroPace's score of 0.87 indicating that Cytosorbents is being referred to more favorably in the media.
Cytosorbents has higher earnings, but lower revenue than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.
Cytosorbents received 412 more outperform votes than NeuroPace when rated by MarketBeat users. Likewise, 79.13% of users gave Cytosorbents an outperform vote while only 55.81% of users gave NeuroPace an outperform vote.
Cytosorbents presently has a consensus target price of $2.00, indicating a potential upside of 127.27%. NeuroPace has a consensus target price of $15.67, indicating a potential upside of 139.55%. Given NeuroPace's stronger consensus rating and higher probable upside, analysts clearly believe NeuroPace is more favorable than Cytosorbents.
Cytosorbents has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, NeuroPace has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500.
32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 6.6% of Cytosorbents shares are owned by company insiders. Comparatively, 22.2% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
NeuroPace beats Cytosorbents on 11 of the 18 factors compared between the two stocks.
Get Cytosorbents News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytosorbents Competitors List
Related Companies and Tools
